What is Group B Strep?
Group B Streptococcus (GBS) is a type of bacteria that can cause illness in people of all ages. In newborns, GBS is a major cause of meningitis (infection of the lining of the brain and spinal cord), pneumonia (infection of the lungs), and sepsis (infection of the blood) (CDC 1996; CDC 2005; CDC 2009).
Group B strep lives in the intestines and migrates down to the rectum, vagina, and urinary tract. All around the world, anywhere from 10-30% of pregnant people are “colonized” with or carry GBS in their bodies (Johri et al. 2006). Using a swab of the rectum and vagina, people can test positive for GBS temporarily, on-and-off, or persistently (CDC 2010).
Being colonized with GBS does not mean that someone will develop a GBS infection. Most people with GBS do not have any GBS infections or symptoms. However, GBS can cause urinary tract infections and GBS infections in the newborn (CDC 2010), and people who have preterm births are 1.7 times more likely to be colonized with GBS during labor than people who do not have preterm births (Valkenburg-van den Berg et al. 2009).
This article focuses on Group B Strep in pregnancy in the United States, along with some information about other countries.
If you would like to support EBB, you can purchase a printer-friendly PDF of this article.
Are some people more likely to carry GBS?
Researchers have looked at the risk factors for GBS in young, non-pregnant women (Feigin, Cherry et al. 2009). People with these factors may be more likely to carry GBS:
- Multiple sexual partners
- Male-to-female oral sex
- Frequent or recent sex
- Tampon use
- Infrequent handwashing
- Less than 20 years old
In pregnant people, researchers have found that the presence of any amount of GBS in the urine makes it more likely that someone will be colonized at 35-37 weeks pregnancy (Perez-Moreno et al. 2017).
How often do newborns become infected with GBS?
There are 2 main types of GBS infection in newborns: early infection and late infection. In this article we will focus on early infection, which occurs in the first 7 days after birth. When a baby has an early GBS infection, symptoms usually appear within the first 12 hours, and almost all babies will have symptoms within 24-48 hours (CDC 2010). In a study of 148,000 infants born between 2000 and 2008, almost all of the 94 infants who developed early GBS infection were diagnosed within an hour after birth—suggesting that early GBS infection probably begins before birth (Tudela et al. 2012).
Early infection is caused by direct transfer of GBS from the mother to the baby, usually after the water breaks. The bacteria travel up from the vagina into the amniotic fluid, and the fetus may swallow some of the bacteria into the lungs—leading to an early GBS infection. Babies can also get GBS on their body (skin and mucous membranes) as they travel down the birth canal. However, most of these “colonized” infants stay healthy (CDC 2010).
In 1993-1994, the American Congress of Obstetricians and Gynecologists and the American Academy of Pediatrics recommended screening all pregnant women for GBS and treating GBS-positive women with intravenous (IV) antibiotics during labor. Since that time, we have seen a remarkable drop in early GBS infection rates in the U.S.—from 1.7 cases per 1,000 births in the early 1990’s, to 0.25 cases per 1,000 births today (CDC 2012).
If someone who carries GBS is not treated with antibiotics during labor, the baby’s risk of becoming colonized with GBS is approximately 50% and the risk of developing a serious, life-threatening GBS infection is 1 to 2% (Boyer & Gotoff 1985; CDC 2010; Feigin, Cherry et al. 2009). As I noted earlier, being colonized is not the same thing as having an early GBS infection– most colonized babies stay healthy.
On the other hand, if someone with GBS is treated with antibiotics during labor, the risk of their infant developing an early GBS infection drops by 80%. So for example, the risk could drop from 1% down to to 0.2%. (Ohlsson 2013)
What is the risk of death if the baby has an early GBS infection?
Researchers have estimated that the death rate from early GBS infection is 2 to 3% for full-term infants. This means of 100 babies who have an actual early GBS infection, 2-3 will die. Death rates from GBS are much higher (20-30%) in infants who are born at less than 33 weeks gestation (CDC 2010).
Although the death rate of GBS is relatively low, infants with early GBS infections can have long, expensive stays in the intensive care unit. Researchers have also found that up to 44% of infants who survive GBS with meningitis end up with long-term health problems, including developmental disabilities, paralysis, seizure disorder, hearing loss, vision loss, and small brains. Very little is known about the long-term health risks of infants who have GBS without meningitis, but some may have long-term developmental problems (Feigin, Cherry et al. 2009; Libster et al. 2012).
Are some newborns more likely to get early GBS disease?
The primary risk factor for early GBS infection is when the pregnant parent carries GBS. However, there are some things that increase the risk of early GBS infection:
- Being African American (CDC 2012)
- Being born at less than 37 weeks (Boyer &Gotoff 1985; Velaphi et al. 2003; Heath et al. 2009)
- A long period between water breaking and giving birth (Boyer &Gotoff 1985; Velaphi et al. 2003; Heath et al. 2009)
- Water broke before going into labor (premature rupture of membranes) (Adair et al. 2003)
- High temperature during labor (> 99.5 F or 37.5 C) (Boyer & Gotoff 1985; Adair et al. 2003; Velaphi et al. 2003; Heath et al. 2009)
- Infection of the uterus (aka “chorioamnionitis”) (Adair et al. 2003)
- Parent previously gave birth to an infant who had an early GBS infection (CDC 2010)
- Intrauterine monitoring during labor (Adair et al. 2003)
- GBS in the urine during pregnancy (Carroll et al. 2016)
- Giving birth for the first time (Carroll et al. 2016)
*The bolded items are the major risk factors. However, about 60% infants who develop early GBS infection have no major risk factors, except for the fact that their mothers carry GBS (Schrag et al. 2002).
How accurate is testing for GBS?
The CDC recommends measuring GBS with a culture test at 35-37 weeks of pregnancy. This is done by swabbing the rectum and vagina with a Q-tip, and then waiting to see if GBS grows. It takes about 48 hours to get the results back. The goal is to get the results back before labor begins (CDC, 2010).
A culture test during labor is considered the “gold standard,” but this method is not used in practice because it takes too long to get results back. In a recent, high-quality study, researchers did the culture test twice– once at 35-36 weeks and once during labor. They compared the 35-36 week test to the gold standard.
Of pregnant people who screened negative for GBS at 35-36 weeks, 91% were still GBS-negative when the gold standard test was done during labor. The other 9% became GBS positive. These 9% were “missed” GBS cases, meaning that these people had GBS, but most (41 out of 42) did not receive antibiotics.
Of the pregnant people who screened positive for GBS at 35-36 weeks, 84% were still GBS positive when the gold standard test was done during labor. However, 16% of the GBS-positive people became GBS-negative by the time they went into labor. These 16% received unnecessary antibiotics (Young et al. 2011).
Is there a faster test that could be used in labor?
It’s possible that a rapid-test for GBS during labor may be a better option for some people, and this has been a hot topic for research over the past few years. In the same study mentioned above, researchers compared the 35-36 week culture test and the in-labor rapid test to the gold-standard test (culture during labor).
The researchers found that the 35-36 week culture test only identified 69% of the pregnant people who actually had GBS during labor. Meanwhile, the in-labor rapid test was much more sensitive—it identified 91% of those with GBS during labor (Young et al, 2011).
Since the Young study, at least two other studies have found that the rapid test identified 100% of people with GBS during labor. (Helmig et al., 2017; Wolheim et al., 2017). However, one “real life” study (with obstetricians and midwives doing the testing) found that the sensitivity of the rapid test was only 86%, and on average, 24% of test swabs were invalid, meaning that a result was not given 24% of the time. More than half (59%) of these invalid results were due to improper handling of the test. An additional 2-hour training of hospital staff lowered the invalid rate from an initial high of 55% down to 13%. (Mueller et al., 2014).
In a 2012 study in France, researchers followed a hospital as it switched from prenatal testing to in-labor testing for GBS. With the in-labor rapid GBS test, more mothers with GBS were identified (17% vs. 12%), there were fewer cases of early GBS infection in newborns (0.5% vs. 0.9%), and the financial cost was the same (El Helali et al. 2012). In another study, researchers estimated that switching from the conventional prenatal test to the rapid test reduced the percentage of people unnecessarily treated with antibiotics from 14% down to 5%. They state that the rapid test strategy does generate extra costs for the hospital, but that these costs could be offset somewhat by decreasing nursing time spent administering unnecessary IV antibiotics or observing uninfected newborns (Poncelet-Jasserand et al. 2013).
One drawback of rapid-testing is that it can still take up to an hour or more to get the results back, and people would have to wait to get antibiotics until the results came in (Honest et al. 2006; Young et al. 2011). In one study, researchers found that the average time it took to receive a result was 75 minutes when the test was conducted by laboratory staff, and 165 minutes when the test was conducted by midwives and obstetricians (Mueller et al. 2014). The CDC says that the ideal rapid test for GBS could be done at the bedside in less than 30 minutes (CDC, 2010).
What is the evidence for antibiotics during labor to prevent early GBS infection?
To answer this question, I will walk you through the most important studies that led to how we most commonly try to prevent early GBS infections in the U.S. today.
GBS emerged as a widespread threat to newborns in the early 1970’s. At that time, 1.7 of every 1,000 infants had early GBS infection (CDC 2010). In 1973, a researcher proposed giving pregnant women penicillin to stop early GBS infections in infants (Franciosi et al. 1973).
First, researchers tried giving penicillin to women before labor, but this didn’t work. Although penicillin temporarily lowered GBS levels, by the time women went into labor the GBS levels were back up again (Gardner et al. 1979).
Next, researchers tried giving antibiotics to those with GBS during labor. In the late 1980’s, three groups of researchers in the U.S., Spain, and Finland randomly assigned women with GBS to either receive IV antibiotics during labor (penicillin or ampicillin) or no antibiotics (Boyer & Gotoff 1985; Tuppurainen and Hallman 1989; Matorras et al. 1991).
In a recent Cochrane review, researchers combined the results of these 3 studies, with a total of 500 pregnant women. They found that when women with GBS had antibiotics during labor, their infants risk of catching early GBS infection dropped by 83% (Ohlsson & Shah 2013).
As the Cochrane reviewers noted, there were quite a few limitations to these 3 studies. In their summary, the reviewers said “There is no valid information from these three small, old, and biased trials to inform clinical practice.” However, an alternative perspective would be that there is some valid information from these studies, along with some limitations to the evidence.
Was the Cochrane review correct in saying that there was no valid information from these studies to inform practice?
The Cochrane Collaboration is a highly respected organization that conducts meta-analyses on different topics related to healthcare. A meta-analysis is a type of research study when researchers pool statistics from previous studies into one large study, and look at the results.
The Cochrane Pregnancy and Childbirth Group has a policy that they only do meta-analyses on randomized, controlled trials. So the Cochrane review on GBS (published in 2009 and “updated” but essentially unchanged in 2013 and 2014) only includes three small randomized, controlled trials, and does not look at other types of evidence, such as evidence from large observational studies where some people received antibiotics and others did not.
Are the results from the Cochrane review concerning?
The researchers who wrote the Cochrane review on Group B Strep came to strong conclusions against the use of antibiotics for Group B Strep. After reviewing the three existing randomized, controlled trials on Group B Strep, they stated “There is no valid information from these three small, old, and biased trials to inform clinical practice…It is remarkable that in North America the commonly implemented practice of intrapartum antibiotic prophylaxis to GBS colonized women has been so poorly studied.”
It is true that these three studies had some major limitations. In fact, most studies published before 1996 suffered from less than optimal written reports of their findings.
In the mid-1990’s, researchers became very concerned about the widespread quality problem with clinical trial reports. So in 1996, researchers from Canada and the U.S. came together and published the CONSORT guidelines for clinical trials.
CONSORT stands for the Consolidated Standards of Reporting Trials, and it is basically an evidence-based checklist of items that researchers must disclose in their article before they can report the results of their studies in most medical journals. Publishing of the CONSORT guidelines forced researchers to be transparent about their methods, and it greatly improved our ability to evaluate the quality of a clinical trial.
The three studies that the Cochrane reviewers critique as being “invalid” were done in 1986, 1989, and 1990, before the CONSORT guidelines were developed. So this partially explains why the written reports of these three studies are not up to today’s standards.
What about their critique of the three randomized trials on antibiotics for Group B Strep?
To help you understand this issue, I would like to present two different ways that you could look at these three clinical trials: the concerns raised by the Cochrane reviewers, and an alternative point of view.
Table: Cochrane Perspective vs. Alternative Perspective
|Cochrane Perspective||Alternative Perspective|
|None of the studies had a placebo treatment. The antibiotics were compared to no treatment.||This would not have changed the findings. The diagnosis of GBS in infants is not subjective or symptom-based, but it is based on culture (lab test) results.|
|Patients, care providers, and researchers were not blinded to the group assignments.||Likewise, this would not have changed the results. Blinding is much more important when the outcome of interest is subjective, like pain or quality of life.|
|The researchers did not do an up-front “power analysis” to determine the appropriate sample size.||It is possible that the researchers conducted a power analysis but did not report it, since power analyses were not required information for medical journals before 1996. Also, the meta-analysis did show a difference in GBS infection rates, so it appears that the studies were adequately powered to observe differences between the groups.|
|The sample sizes were likely too small to detect differences in early GBS infection and mortality.||But the studies did show a difference in early GBS infection rates. True, larger studies may have been better able to detect a difference in mortality rates, but it would take a very large sample, and such a study may not be practical or ethical given that the researchers found a decrease in GBS infection rates.|
|Only one of the three studies specifically looked at mortality.||Yes, this is a limitation, but we are interested in GBS infections, because they are a big deal. Infants are in the ICU for many weeks. This is traumatic, can have long term health effects, and also costs a lot of money.|
|Boyd et al. published their results and then announced that they only needed one more event in the control group to achieve statistical significance. After this one event happened, they re-published the study with the new “significant” finding. This indicates a high level of bias and possible manipulation of the study findings.||This is not ideal, but it is not uncommon for researchers to do a preliminary data analysis, find that there is a “trend” towards statistical significance, and then continue collecting more data. A trend towards significant results often indicates that the study needs only a slightly larger sample size in order to determine differences between groups.|
|Boyd et al. improperly tweaked their statistics (switched from a 2-tailed test to a 1-tailed test) so that the results were changed from “not significant” to “statistically significant.”||In current times, researchers would have handled this differently by doing something called a “sensitivity analysis” and appropriately explained what they were doing.|
|Boyd et al. excluded all women who developed a fever from their statistics, which is incredible considering the fact that fever is a risk factor for early GBS infection.||The researchers excluded women with fever because all these women needed to receive antibiotics—they ethically could not stay in an untreated group. Therefore they were not eligible to be in this ‘preventive trial’. This was an appropriate thing to do.|
|They were missing final results for 11% of women and infants in the study.||Yes, but it is unlikely that any of these missing individuals had GBS infections or were septic. Nowadays, there is a different type of analysis that we could have done to account for the missing data.|
In summary, although these three studies had limitations (not uncommon for research published before 1996), there was also some valid information that we can use.
Although it would be best if we had modern, larger, randomized, controlled trials on antibiotics for Group B Strep, such trials would be very impractical and highly unlikely to be carried out, given that antibiotics are already in routine use. Furthermore, we have newer evidence from large observational studies that we can use to look at the potential benefits and risks of antibiotics for Group B Strep.
Based on information from the 3 original randomized, controlled trials, in 1996, the CDC initially recommended 2 ways to prevent early GBS infections:
- The “universal approach.” Screen all pregnant people at 35-37 weeks and treat everyone who is positive with antibiotics during labor (this is the method that is currently used in the U.S.)
- The “risk-based approach.” Treat laboring people with antibiotics if they have one or more of these risk factors: GBS in the urine at any point in pregnancy, previously gave birth to an infant with early GBS infection, goes into labor at less than 37 weeks, has a fever during labor, or water has been broken for more than 18 hours (this is the method that is currently used in the United Kingdom)
In 2002, the CDC revised their guidelines to recommend the universal approach.
This decision was based on an important study published in the New England Journal of Medicine (Schrag et al. 2002). In this study, researchers used CDC lab results and chart reviews to look at 629,912 live births that took place in the U.S. between the years 1998-1999.The researchers randomly selected 5,144 of these births to study, plus all 314 infants who were born with early GBS. They used hospital records to label people as receiving the universal approach (52%) or the risk-based approach (48%).
The results? There were 0.5 infants born with GBS per every 1,000 pregnant parents. People in both groups received antibiotics about a third of the time. But people whose care providers used the universal approach had a 54% reduction in the risk of early GBS infection compared to people whose care providers used the risk-based approach. This means that the universal approach worked better than the risk-based approach.
In 2002-2003, the same group of researchers looked at 819,528 births in the U.S. to see whether the revised guidelines had been put into practice. Like the previous study, the researchers picked a random sample of birthing people and infants to analyze, along with the 254 infants who had early GBS infection. Between 1999 and 2002, use of the universal approach rose from about 50% to 85%, and use of antibiotics during labor rose from 27% to 32%.
This time around, there were 0.32 infants born with early GBS per every 1,000 birthing people (down from 0.5 cases per 1,000 only four years earlier). When researchers looked at the infants born at 37 weeks or later who had early GBS, only 18.0% were born to pregnant parents who were not screened. Most of the cases of GBS in term infants (61%) happened in pregnant parents who had been screened but tested negative for GBS. The researchers concluded that universal screening and antibiotic use cannot be expected to prevent 100% of early GBS infections, and that if we want to further lower GBS infection rates, then we will need access to rapid testing and vaccines against GBS (Van Dyke et al. 2009).
What is the best time to receive antibiotics for GBS?
The CDC recommends that antibiotics be given every 4 hours, starting more than 4 hours before birth. Recent evidence supports these recommendation:
In 2013, researchers looked at 7,691 live births that took place during 2003-2004 in the U.S. (randomly selected out of >600,000 births), along with 254 infants who had early GBS infection (Fairlie et al., 2013). About 1 in 3 birthing people had antibiotics during labor (31%), and 59% of those received antibiotics more than 4 hours before birth.
When penicillin or ampicillin was given more than 4 hours before birth, it was effective 89% of the time. In contrast, giving antibiotics 2-4 hours before birth was effective 38% of the time. Antibiotics given less than 2 hours before birth were effective 47% of the time. When Clindamycin (another antibiotic) was used in place of penicillin, it worked very poorly (only 22% effective). There was no statistical difference between the 2-4 hour window and the 2-0 hour window, so even though the percentages look different, they are not statistically significant.
In another study published in 2013, researchers reviewed the medical records of 4,756 birthing people who received antibiotics during labor for GBS– 1,149 received antibiotics for less than 4 hours, and 3,633 receiving antibiotics for 4 or more hours. More infants whose mothers received less than 4 hours of antibiotics had a discharge diagnosis of sepsis when compared to infants whose mothers received 4 hours or more of antibiotics (1.4% versus 0.4%.) (Turrentine et al., 2013).
Finally, a study carried out in Uruguay in 2015 followed 60 carriers of GBS at term who came to the hospital in early labor. They swabbed each person for GBS before antibiotics were started, and then again 2 and 4 hours after the first dose of penicillin was given. The researchers found that 72% of the participants were GBS positive before antibiotics were started, 47% were positive 2 hours after the first dose, and only 12% were positive for GBS 4 hours after the first dose. In all 60 newborns, the cord blood and amniotic fluid reached therapeutic levels of penicillin, even though 28% of the women gave birth before 4 hours. The maximum effect of the antibiotics was reached at 4 hours, just before the next dose was due (Scasso et al. 2015).
How will antibiotics during labor affect a newborn’s microbiome?
When this Evidence Based Birth® article was first published in early 2014, I could not find any evidence on the effects of in-labor antibiotics for GBS on the newborn’s microbiome. However, since that time, I have found 8 studies in which researchers have looked at the microbiota consequences of IV antibiotics during labor for Group B Strep.
In these studies (Table 1), researchers enrolled infants whose mothers had IV antibiotics during labor (typically for GBS) and compared them to infants whose mothers did not have IV antibiotics during labor. Most researchers studied the infant microbiome by collecting and analyzing stool samples at time points ranging from 3 days of life to 1 year of age.
Overall, researchers found that receiving IV antibiotics during labor does impact the infant’s microbiome, at least temporarily. Seven of eight studies found that IV antibiotics during labor had at least a short-term effect on reducing beneficial bacteria and/or increasing levels of non-beneficial bacteria. Of the four studies that followed the infant microbiome over time, two found that the infant’s microbiome had either recovered or mostly recovered by 4-8 weeks, while two other studies found important differences that persisted up to 3 months or a year later in some infants.
Perhaps the most important study on this topic, and the only study to follow infants for a year, was conducted by researchers in Canada. In 2016, Azad et al. studied 198 mother-infant pairs from a large Canadian cohort study. Infants could be included in the microbiome study if they had stool samples collected at 3 months and 1 year, and if they had complete information about antibiotic exposure during labor and infancy.
Infants were separated into 4 groups: no antibiotic exposure during labor with vaginal birth (57%), antibiotic exposure with vaginal birth (21%), antibiotic exposure with elective Cesarean (9%), and antibiotic exposure with unplanned Cesarean (13%). Cefazolin was the antibiotic that was typically used during Cesareans, and penicillin was the antibiotic of choice for vaginal births. Researchers also measured the presence and duration of exclusive breastfeeding.
The results showed that the infant microbiome was influenced by antibiotic exposure during labor, birth route (Cesarean or vaginal birth), and breastfeeding. At 3 months, infants exposed to antibiotics during labor or birth had a decreased level of Bacteroidetes (a beneficial bacteria), as well as a decrease in the “richness” of their microbiome, regardless of whether they were exclusively breastfed or not. The most severe deficiencies happened among infants born by Cesarean. Infants born by Cesarean also had higher levels of Clostridium, Enterococcus, and Streptococcus—potentially harmful bacteria. At one year of age, most of these differences were gone, showing that the effect on the microbiome was short-term. However, some negative effects on the microbiome still persisted in infants born by unplanned Cesarean who had not been breastfed for at least 3 months.
The changes in the microbiome seen in all of these studies are consistent with what one would expect after administering IV antibiotics, like ampicillin, that mainly act against gram-positive bacteria. Killing off gram-positive bacteria (like Group B Strep) can lead to an over-abundance of gram-negative bacteria. Also, some beneficial bacteria, like Bacteroidetes, are sensitive to penicillin and ampicillin, meaning that they are also killed off by the antibiotic.
In summary, it does appear that IV antibiotics during labor have a short-term negative effect on the infant’s microbiome, but that this negative effect can be lessened by breastfeeding. Research is needed to determine if giving probiotics to mothers and/or newborns can help lessen or reverse the impact of IV antibiotics on the infant’s microbiome. Research is needed to determine if there are any long-term effects associated with the temporary reduction in beneficial bacteria.
What are the potential benefits and harms of the universal screening and treatment approach?
- In clinical trials, using antibiotics (penicillin or ampicillin) during labor decreases the risk of early GBS infection by 83%, although there are limitations to the quality of this evidence (Ohlsson 2013)
- Penicillin rapidly crosses the placenta into the fetal circulation (at non-toxic levels) and can prevent GBS from growing in the fetus or newborn (CDC 2010; Barber et al. 2008).
- In large studies in the U.S., the universal approach (screening and treating all GBS-positive pregnant parents with antibiotics during labor) is associated with lower rates of GBS infections than giving antibiotics based on risk factors alone (Schrag et al. 2002).
- Most research has found that antibiotic resistance has not been a problem with penicillin, the drug most commonly used to prevent early GBS infection (CDC 2010; Melo et al. 2016). However, one recent study found a 12% resistance rate in Italy (Matain et al. 2016).
- Although rare, severe allergic reactions have been reported. The risk is estimated to be 1 in 10,000 for a severe reaction, and 1 in 100,000 for a fatal reaction. (Weiss and Adkinson 1988).
- IV antibiotics have been shown to cause a short-term negative effect on the infant’s microbiome; however, most infants will experience a recovery of their microbiome, and this recovery is enhanced by breastfeeding.
- There is an increase in the risk of maternal and newborn yeast infections, which can harm the breastfeeding relationship. In one study, 15% of women who received antibiotics in labor had mother-baby yeast infections (maternal nipple and infant mouth infections), compared to 7% of mothers who did not have antibiotics (Dinsmoor et al. 2005).
- Other potential harms have to do with side effects related to the antibiotic that is used (click on the link to see a comprehensive list of potential side effects for each antibiotic, but keep in mind that most of the serious risks are rare): Penicillin, ampicillin, cefazolin, clindaymycin, and vancomycin.
- The potential medicalization of labor and birth (RCOG 2003).
What are the best antibiotics for someone who is allergic to penicillin?
Many people who have an allergy to penicllin can take Cefazolin instead. One advantage to Cefazolin is that (like penicillin) it crosses the placenta and reaches the fetus’s bloodstream. If someone is at high risk for anaphylaxis with penicillin (click here to find out more), then the CDC recommends several different antibiotics instead of Cefazolin. Which antibiotic a birthing person can take depends on the results of their GBS lab tests. Alternative antibiotics include clindaymycin and vancomycin.
Unfortunately, clindamycin and vancomycin have never been tested in clinical trials for the prevention of early GBS infection. Clindamycin faces high rates of drug resistance, barely reaches the fetal bloodstream, and should never be used unless the pregnant parent’s GBS has been specifically tested and it is known that these antibiotics will work on their particular strain of GBS. Vancomycin can be used in someone who is highly allergic to penicillin and whose GBS is resistant to clindamycin. However, Vancomycin barely crosses the placenta to get into the fetal circulation, making it less effective against a developing GBS infection.
Also, the effects of these more broad-spectrum antibiotics on the infant’s microbiome are unknown, but it is possible that these antibiotics may have a stronger effect on the infant’s microbiome, given their effectiveness against a broader range of bacteria. Finally, although some care providers may use erythromycin to prevent early GBS, the CDC states that erythromycin should never be used to prevent early GBS infection (CDC, 2010; Pacifici 2006).
If I have antibiotics, does this mean I will be continuously hooked up to an IV?
Not necessarily. If you use the antibiotics, you will have an IV placed, but it only takes 15-30 minutes for the antibiotics to run in. The antibiotics are only given every 4 hours until birth, which for many people is only once or twice. When the IV is running, it should not limit positioning, walking, or even laboring in water.
For the hours in between, parents can ask for the IV can be “hep-locked” or “saline-locked” and detached, so that you are free from the IV pole. For more information about saline locks, please read my article about saline locks during labor here.
For low-risk, healthy pregnant people, it is a very reasonable request to ask for the IV to be hep-locked or saline-locked in between antibiotic doses. For more information on IV fluids during labor, please read this article here. To learn about the evidence for eating and drinking during labor,
Are there any other options?
One alternative to the universal approach is the “risk-based approach.” This is when you receive antibiotics based on other risk factors such as having a fever or your water being broken for more than 18 hours. This alternative is no longer recommended by the CDC. The number of birthing people who receive antibiotics is roughly the same whether you choose the universal approach or the risk-based approach—about 30%. However, as already mentioned, evidence from large observational studies shows that the universal approach is more effective than giving antibiotics based on risk factors alone.
Chlorhexadine (aka Hibiclens)
Chlorhexadine is a topical disinfectant that kills bacteria on contact. It binds easily to the skin and mucous membranes. In the vagina, the anti-GBS effects of chlorhexadine last from 3-6 hours. Chlorhexadine has been shown to be safe, is easy to administer, and only costs a few cents per use (Goldenberg et al. 2006). Hibiclens is a brand formulation that includes chlorhexadine. Most of the research studies have used chlorhexadine; however, in the U.S., many midwives can only access Hibiclens.
In a Cochrane review that was updated in 2014 (Ohlsson et al. 2014), researchers combined results from 4 randomized, controlled trials that compared vaginal chlorhexadine vs. a placebo or no treatment on outcomes of 1,125 infants born to women who were GBS positive. The evidence from these studies was judged to be of very low quality. The researchers removed a 5th trial that had been included in previous versions of the Cochrane review, because it did not include women with known positive GBS status. They also corrected a data analysis mistake from the previous version.
In this updated review, the Cochrane reviewers found that chlorhexidine does not reduce the infants’ risk of being colonized with GBS. They also found no difference in early GBS infection rates between people who used the chlorhexadine and those who did not. There were no cases of infant deaths from GBS in either group. The chlorhexadine group had higher rates of the side effects of stinging and irritation. The researchers called for a large clinical trial to test chlorhexadine for the prevention of early GBS.
Chlorhexadine may potentially be beneficial for pregnant people living in low-resource countries where access to antibiotics is limited. In their review of the literature, Goldenberg et al. (2006) found 2 studies from developing countries (Egypt and Malawi) where researchers tested chlorhexadine in the vagina every 4 hours during labor and then wiped the newborn with chlorhexidine shortly after birth. This is a lower level of evidence than the studies listed above, because neither of these were randomized, controlled trials. Instead, the researchers followed hospitals over a period of months when: 1) they did not use chlorhexadine, 2) they used chlorhexadine, and 3) they stopped using chlorhexadine. In both studies, researchers found that when chlorhexadine was used in both the vagina and wiped all over the newborn, there were immediate drops in newborn hospital admissions, newborn sepsis (blood infection) admissions, and newborn deaths due to infections. Unfortunately, researchers did not specifically count the number of GBS infections, just the overall number of babies who had admissions for sepsis.
So is chlorhexadine effective? Randomized, controlled trials show that in developed countries, applying chlorhexadine topically during labor does not make any difference in GBS colonization or early GBS infection rates. However, evidence from developing countries shows that chlorhexadine vaginal wipes PLUS newborn wipes may reduce sepsis rates in general. Chlorhexidine might be better than nothing, but it cannot prevent the ascent of GBS in the amniotic fluid unless it is given before the birthing person’s water breaks and repeated before its effect wears off. Unlike IV antibiotics, there is no evidence that chlorhexadine can stop GBS from growing in the fetus before birth.
Garlic has antibacterial properties, and some websites recommend putting garlic in the vagina to eliminate GBS before the GBS test. However, there is very little evidence to back up this treatment. One group of researchers put garlic extract and GBS in a petri dish together (Cutler et al., 2009). They found that the garlic was able to kill the GBS within about 3 hours. However, this treatment has never been tested in a scientific study with humans. Also, it’s important to understand that back in the 1970’s when researchers tried using penicillin during pregnancy, they found that the antibacterials temporarily lower levels of GBS, but levels almost always go up again by the time someone goes into labor. So by temporarily using garlic, this could help you get a negative test result, but the effect may wear off very quickly.
In a letter to the editor in a medical journal, Cohain (2009) described treating 8 women with long-term GBS infections using a half clove of freshly cut garlic, inserted into the vagina at bedtime and removed in the morning for 3 to 6 weeks, with maintenance doses used every 2-4 days. However, none of these women were pregnant, and all of them had active infections.
Based on this one small case report we do not have any research evidence yet to inform this practice in pregnant people who are colonized with GBS– meaning we have little evidence about the potential benefits and harms. For example, it is possible that long-term garlic or chlorhexidine use could potentially or theoretically have unexpected effects like premature rupture of membranes or increase other bacteria– even GBS– due to destruction of good bacteria, like lactobacilli. Until researchers examine the potential benefits and harms, there are a lot of unknowns related to this treatment.
Vaccines for GBS are under development, but are not available yet at this time (World Health Organization, 2005; Heath 2016). There is a push for a GBS vaccine for several reasons: 1) in-labor antibiotics do not prevent GBS infection 100% of the time (Velaphi et al., 2003), 2) in-labor antibiotics can have side effects, 3) in-labor antibiotics do not prevent other GBS problems, such as preterm labor or late-onset GBS disease in newborns, and 4) developing countries have not been able to implement widespread use of antibiotics for GBS during labor.
Taking probiotics (lactobacilli) may lessen your chances of being colonized with GBS. In 2016, researchers published the first randomized trial on using probiotics to switch GBS status from positive to negative (Ho et al. 2016). In this study, researchers randomly assigned 110 women in Taiwan who were GBS positive at 35-37 weeks to take either two probiotic capsules each night at bedtime, or two placebo capsules. Both the pregnant women and the researchers were blinded to the treatment, meaning that nobody knew who was taking a placebo or probiotic while the study was being carried out. The treatment for each person lasted 3 weeks on average, and the GBS culture test was repeated when women returned to the hospital to give birth. The results showed that 43% of GBS positive people who took probiotics were GBS negative when they went into labor, compared to 14% in the placebo group. The researchers state that although more research is needed, probiotics show promise for GBS prevention during pregnancy and birth.
The results from the Ho et al. randomized trial are supported by several “in vitro” (petri dish based) studies. In these studies, researchers put vaginal lactobacilli (including a commercially available version) in a petri dish with different strains of GBS. They found that the lactobacilli strongly inhibited the growth of GBS by increasing the acidity of the environment (Acikgov, 2005— article in Turkish; Zarate, 2006).
In another small clinical trial, researchers randomly assigned healthy, fertile (but non-pregnant) women to wear panty liners that were saturated with probiotics, or to wear placebo panty liners. The results showed that it is possible to transfer probiotics to the vagina using panty liners. The researchers also found that people who had higher levels of lactobacilli in the vagina had lower levels of GBS (Rönnqvist PD, 2007).
There is one larger clinical trial going on right now in which researchers are studying the effects of probiotics on Group B Strep colonization in pregnant people. Hopefully this study will give us more information about the potential effects of probiotics on GBS in pregnancy. The study is scheduled to finish recruiting in 2019. Read more.
A few websites mention colloidal silver as a remedy for preventing GBS infection. Although silver has anti-bacterial properties, no known research studies have ever been conducted on taking colloidal silver to prevent a GBS infection—and no studies have ever looked at the safety of colloidal silver in pregnancy. The potential benefits and harms of this substance are unknown. In 1997, the FDA stated that colloidal silver is not safe or effective for any condition.
Can infants acquire a GBS infection from staff handling the newborn?
Researchers are quite certain that infants catch early GBS infections before they are born—most likely from GBS in the amniotic fluid. As mentioned earlier, almost all infants with early GBS infection show symptoms within an hour after birth. However, infants can catch “late” GBS infections from the hospital (nursery, hands of hospital staff and family members) or the community. This is one reason hand-washing is so important (Kliegman et al. 2011).
If I am GBS positive, and I don’t get the IV antibiotics for some reason, what kind of tests will my baby need to have?
As long as your baby appears to be doing well and you did not have any additional risk factors (<37 weeks, infection of the uterus, water broken >18 hours), then there is no need for your baby to have any special testing. There are some situations where the CDC recommends that a well-appearing infant have some blood tests. The CDC also recommends 48 hours of “observation” for infants who are born to GBS positive mothers, but there is no need to separate mom and baby for this observation period. To see the CDC’s flow-chart with more details about newborn testing and observation, click here.
What do national organizations have to say?
In the United States:
In 2010, the U.S. Centers for Disease Control and Prevention recommended universal screening for GBS at 35-37 weeks and in-labor antibiotics for all women who test positive.
These recommendations are supported by the:
- American Congress of Obstetricians and Gynecologists
- American Academy of Pediatrics
- American College of Nurse-Midwives
- American Academy of Family Physicians
- American Society for Microbiology
In the United Kingdom:
- The United Kingdom National Screening Committee states that pregnant people in the UK should not be screened for GBS. The UK follows the risk-based approach. This includes giving antibiotics in-labor to all women who have fever, prolonged rupture of membranes >18 hours, GBS in urine at any time during pregnancy, preterm labor, or a prior infant with GBS. This means that many people who are actually GBS negative receive antibiotics directed at GBS, just based on their risk factors. In the UK, the rate of early GBS infections is 0.5 per 1,000 births, which is higher than the rate of 0.2 per 1,000 births in the U.S.
- The Royal College of Obstetricians does not recommend routine screening for GBS during pregnancy. However, they do state that in-labor antibiotics could be considered if GBS was detected in passing or if women have any of the risk factors listed above. Many people are already receiving antibiotics for these reasons.
- There is controversy in the UK over the lack of access to GBS testing within the National Health Service. Group B Strep Support is a consumer-based charity that advocates for women to have access to GBS screening in the UK.
- The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends offering GBS screening to all pregnant people and treating those who are positive with IV antibiotics.
- The Association of Ontario Midwives recommends GBS screening and has a great article for midwives to use in helping women make an informed choice regarding the treatment strategy.
In New Zealand
- In 2014, multiple professional organizations released a consensus statement recommending that the risk-based approach should continue to be used in New Zealand. They mention that this recommendation may need to be revised once rapid-screening becomes more available. The rate of early onset GBS disease in New Zealand is comparable to the U.S., with 0.26 cases per 1,000 births.
What is the bottom line?
- In the U.S., screening and treating all GBS-positive people with antibiotics during labor has been associated with lower rates of early GBS infections in newborns than giving antibiotics based on risk factors alone.
- There are both potential benefits and potential harms related to screening for GBS and giving antibiotics– talk with your treating healthcare provider about the best course of action for you.
- Research has shown that IV antibiotics negatively effects the infant microbiome, but for most infants these effects seem to be temporary, and breastfeeding can help lessen the negative effects.
- Since two-thirds of remaining early GBS infections are now due to false negative GBS test results, in the future more hospitals may begin to use the rapid in-labor test for GBS. The rapid test may help reduce the number of people who receive unnecessary antibiotics.
- The first randomized trial on using probiotics to reduce GBS colonization in pregnant people had promising results, with 43% of GBS positive women becoming GBS negative by the time of birth
- We do not have evidence to show that topical chlorhexidine or garlic use can prevent early GBS infections, since GBS infection usually occurs when GBS gains access to the amniotic fluid and gets into the fetus’ lungs during labor.
I would like to acknowledge my reviewers for helping maintain the quality of articles published at Evidence Based Birth. In particular, I would like to acknowledge Dr. Jessica Illuzzi, Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences, and researcher who studies Group B Strep at Yale School of Medicine, for her expert review and assistance in writing the original article published in 2014. I would also like to acknowledge Robert Modugno, MD, FACOG, and Shannon J. Voogt, MD, Board-Certified in Family Medicine, and 2 other anonymous reviewers (a GBS researcher and a microbiologist) for their review of the original article. This article was since updated by Rebecca Dekker, PhD, RN, APRN, in 2017, with the revisions reviewed by Julie Le, Microbiologist, Birth Doula CD (DONA), and Evidence based Birth® Instructor and Shannon J. Voogt, MD, Board-Certified in Family Medicine.
Thank you for your support:
All Evidence Based Birth® Signature Articles are publicly available on our website for free.
If you would like to help support Evidence Based Birth®, please feel free to purchase the printable versions of our Signature Articles to share with clients or take to doctors’ appointments. ( You can purchase them individually or save 58% and purchase them all )
If you are a birth professional, you have the option to become a Professional Member and get immediate access to all of our printable Signature Articles plus many other benefits.
- Adair, C. E., L. Kowalsky, et al. (2003). “Risk factors for early-onset group B streptococcal disease in neonates: a population-based case-control study.” CMAJ 169(3): 198-203.
- Ackigov, Z. C., S. Gamberzade et al. (2005). “Inhibitor effect of vaginal lactobacilli on group B streptococci.” Mikrobiyol Bul 39(1): 17-23. (Article in Turkish and unable to translate).
- Aloisio, E., Mazzola, G., Corvaglia, L. T., et al. (2014). “Influence of intrapartum antibiotic prophylaxis against group B Streptococcus on the early newborn gut composition and evaluation of the anti-Streptococcus activity of Bifidobacterium strains. Appl Microbiol Biotechnol 98: 6051-6060.
- Aloisio, I., Quagliariello, A., De Fanti, S., et al. (2016). Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions.” Appl Microbiol Biotechnol 100(12): 5537-46.
- Azad, M. B., Konya, T., Persaud, R. R. (2015). “Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study.” BJOG 123: 983-993.
- Barber, E. L., G. Zhao, et al. (2008). “Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery.” Obstetrics and gynecology 112(2 Pt 1): 265-270.
- Boyer, K. M. and S. P. Gotoff (1985). “Strategies for chemoprophylaxis of GBS early-onset infections.” Antibiot Chemother 35: 267-280.
- Carroll, A., Eogan, M., Monteith, C., et al. (2016). “Case-control study of neonatal group B streptococcal disease risk factors in a Dublin maternity hospital over a 13-year period.” Int J Gynaecol Obstet 135(1): 117-8.
- Centers for Disease Control and Prevention (CDC) (2009). “Trends in perinatal group B streptococcal disease- United States, 2000-2006.” MMWR Morb Mortal Wkly Rep 58: 109-112.
- CDC (2010). “Prevention of perinatal group b streptococcal disease.” MMWR 59: 1-32.
- CDC (2012). “ABCs report: Group B streptococcus, 2010.” Retrieved March 10, 2013.
- CDC (1996). “Prevention of perinatal group B streptococcal disease: a public health perspective. .” MMWR Recomm Rep 45: 1-24.
- CDC (2005). “Early-onset and late-onset neonatal group B streptococcal disease– United States, 1996-2004.” MMWR Morb Mortal Wkly Rep 54: 1205-1208.
- Cohain (2009). “Long-term symptomatic group B streptococcal vulvovaginitis: eight cases resolved with freshly cut garlic.” European Journal of Obstetrics & Gynecology and Reproductive Biology 146(1): 110-111.
- Corvaglia, L., Tonti, G., Martini, S., et al. (2016). “Influence of intrapartum antibiotic prophylaxis for Group B Streptococcus on gut microbiota in the first month of life.” JPGN 62: 304-308.
- Cutler, R. R., Odent M, et al. (2009). In vitro activity of an aqueous allicin extract and a novel allicin topical gel formulation against Lancefield group B streptococci. J Antimicrob Chemother 63(1): 151-154. .
- Dinsmoor, M. J., R. Viloria, et al. (2005). “Use of intrapartum antibiotics and the incidence of postnatal maternal and neonatal yeast infections.” Obstetrics and gynecology 106(1): 19-22.
- El Helali, N., Y. Giovangrandi, et al. (2012). “Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries.” Obstetrics and gynecology 119(4): 822-829.
- Fairlie, T., E. R. Zell, et al. (2013). “Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group b streptococcal disease.” Obstetrics and gynecology 121(3): 570-577.
- Feigin, R. D., J. D. Cherry, et al. (2009). Textbook of Pediatric Infectious Diseases, Saunders.
- Fouhy, F. et al. (2012). “High-Throughput Sequencing Reveals the Incomplete, Short-Term Recovery of Infant Gut Microbiota following Parenteral Antibiotic Treatment with Ampicillin and Gentamicin.” Antimicrob Agents Chemother 56(11): 5811–5820.
- Franciosi, R. A., J. D. Knostman, et al. (1973). “Group B streptococcal neonatal and infant infections.” J Pediatr 82(4): 707-718. Click here.
- Gardner, S. E., M. D. Yow, et al. (1979). “Failure of penicillin to eradicate group B streptococcal colonization in the pregnant woman. A couple study.” Am J Obstet Gynecol 135(8): 1062-1065.
- Goldenberg, R. L., E. M. McClure, et al. (2006). “Use of vaginally administered chlorhexidine during labor to improve pregnancy outcomes.” Obstetrics and gynecology 107(5): 1139-1146.
- Heath, P. T., G. F. Balfour, et al. (2009). “Group B streptococcal disease in infants: a case control study.” Arch Dis Child 94(9): 674-680.
- Heath, P. T. (2016). “Status of vaccine research and development of vaccines for GBS.” Vaccine 34(26): 2876-9.
- Helmig, R. B., &v Gertsen, J. B. (2017). “Diagnostic accuracy of polymerase chain reaction for intrapartum detection of group B strep colonization.” Acta Obstet Gynecol Scand. Epub ahead of print.
- Ho, M., Chang, Y., Chang, W. (2016). “Oral Lactobacillus rhamnosusGR-1 and Lactobacillus reuteriRC-14 to reduce Group BStreptococcus colonization in pregnant women: A randomized controlled trial.” Taiwan J Obstet Gynecol 55(4): 515-8.
- Honest, H., S. Sharma, et al. (2006). “Rapid tests for group B Streptococcus colonization in laboring women: a systematic review.” Pediatrics 117(4): 1055-1066.
- Johri, A. K., L. C. Paoletti, et al. (2006). “Group B Streptococcus: global incidence and vaccine development.” Nat Rev Microbiol 4(12): 932-942.
- Keski-Nisula, L., Kyynarainen, H. R., Karkkainen, U., et al. (2013). “Maternal intrapartum antibiotics and decreased vertical transmission of Lactobacillus to neonates during birth.” Acta Paediatr 102(5): 480-5.
- Kliegman, R. M., B. F. Stanton, et al. (2011). Nelson Textbook of Pediatrics, Saunders.
- Libster, R., K. M. Edwards, et al. (2012). “Long-term outcomes of group B streptococcal meningitis.” Pediatrics 130(1): e8-15.
- Mandell, G. L., J. E. Bennett, et al. (2010). Principles and practice of infectious diseases, Elsevier.
- Matani, C., Trezzi, M., Matteini, A., et al. (2016). “Streptococcus agalactiae: prevalence of antimicrobial resistance in vaginal and rectal swabs in Italian pregnant women.” Infez Med 24(3): 217-21.
- Matorras, R., A. Garcia-Perea, et al. (1991). “Maternal colonization by group B streptococci and puerperal infection; analysis of intrapartum chemoprophylaxis.” Eur J Obstet Gynecol Reprod Biol 38(3): 203-207.
- Mazzola, G., Murphy, K., Ross, R. P., et al. (2016). “Early gut microbiota perturbations following intrapartum antibiotic prophylaxis to prevent Group B Streptococcal disease. PLoS ONE 11(6): e015727.
- Melo, S. C., Santos, N. C., Oliveira, M., et al. (2016). “Antimicrobial susceptibility of Streptococcus agalactiae isolated from pregnant women.” Rev Inst Med Trop Sao Paulo 58: 83.
- Mueller, M., Henle, A., Droz, S., et al. (2014). “Intrapartum detection of Group B streptococci colonization by rapid PCR-test on labor ward.” Eur J Obstet Gynecol Reprod Biol 176: 137-41.
- Ohlsson, A. and V. S. Shah (2013). “Intrapartum antibiotics for known maternal Group B streptococcal colonization.” Cochrane Database Syst Rev 1: CD007467.
- Ohlsson, A., Shah, V.S., and Stade, B. C. (2014). “Vaginal chlorhexidine during labor to prevent early-onset neonatal group B streptococcal infection.” Cochrane Database Syst Rev: CD003520.
- Perez-Moreno, M. L., Pico-Plana, E., Grande-Armas, J., et al. (2017). “Group B streptococcal bacteriuria during pregnancy as a risk factor for maternal intrapartum colonization: a prospective cohort study.” J Med Microbiol 66(4): 454-460.
- Poncelet-Jasserand, E., Forges, F., Varlet, M. N., et al. (2013). “Reduction in the use of antimicrobial drugs following the rapid detection of Streptococcus agalactiae in the vagina at delivery by real-time PCR assay.” BJOG 120(9): 1098-108.
- Ronnqvist, P.D., U. B. Forsgren-Brusk, et al. (2006). “Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH.” Acta Obstet Gynecol Scand 85(6): 726-735.
- Scasso, S., Laufer, J., Rodriguez, G., et al. (2015). “Vaginal group B streptococcus status during intrapartum antibiotic prophylaxis.” Int J Gynaecol OObstet 129(1): 9-12.
- Schrag, S. J., E. R. Zell, et al. (2002). “A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.” N Engl J Med 347(4): 233-239.
- Tudela, C. M., R. D. Stewart, et al. (2012). “Intrapartum evidence of early-onset group B streptococcus.” Obstetrics and gynecology 119(3): 626-629.
- Tuppurainen, N. and M. Hallman (1989). “Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients.” Obstetrics and gynecology 73(4): 583-587.
- Turrentine, M.A. et al. (2013). “Duration of Intrapartum Antibiotics for Group B Streptococcus on the Diagnosis of Clinical Neonatal Sepsis.” Infect Dis Obstet Gynecol 2013: 525878.
- Van Dyke, M. K., C. R. Phares, et al. (2009). “Evaluation of universal antenatal screening for group B streptococcus.” N Engl J Med 360(25): 2626-2636.
- Velaphi, S., J. D. Siegel, et al. (2003). “Early-onset group B streptococcal infection after a combined maternal and neonatal group B streptococcal chemoprophylaxis strategy.” Pediatrics 111(3): 541-547.
- Weiss, M. E. and N. F. Adkinson (1988). “Immediate hypersensitivity reactions to penicillin and related antibiotics.” Clin Allergy 18(6): 515-540.
- State of the art of vaccine research and development: Initiative for Vaccine Research. 2005. [online]
- Wolheim, C., Sperhacke, R. D., Fontana, S. K. R., et al. (2017). “Group B Streptococcus detection in pregnant women via culture and PCR methods.” Rev Soc Bras Med Trop 50(2): 179-183.
- Young, B. C., L. E. Dodge, et al. (2011). “Evaluation of a rapid, real-time intrapartum group B streptococcus assay.” Am J Obstet Gynecol 205(4): 372 e371-376.
- Zarate, G. & Nader-Macias, M. E. (2006). “Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells.” Lett appl Microbiol 43(2): 174-178.
Summary of Studies on IV antibiotics for GBS and the Newborn Microbiome
|First Author (Year)||Sample and Methods||Results||Notes|
free PMC article PMC525278
|Researchers collected stool samples from 50 newborns in France on day 3 after birth. Half of the infants were born to mothers who had IV amoxicillin for GBS during labor, while the other half did not. Infants were matched for gestational age, vaginal or Cesarean birth, and breastfeeding or bottle feeding.||49 of the 50 infants were colonized with bacteria by day 3 of life. The only infant who was not colonized came from the antibiotics group. Bacterial colonization was similar between groups, but there were fewer infants colonized with C. difficile (a harmful bacteria) in the antibiotic group. They also found no difference in colonization rates with antibiotic-resistant strains of bacteria.||This was the first study that compared bacterial colonization among infants whose mothers received IV antibiotics for GBS, versus those whose mothers did not have GBS or IV antibiotics.|
|Fouhy (2012)||Researchers examined the gut microbiota of 9 newborns who were given IV ampicillin and gentamicin within 48 hours of birth. They took stool samples 4 and 8 weeks after the infants completed their antibiotics, and compared the results to 9 untreated infants.
|Infants who received antibiotics shortly after birth had much lower levels of beneficial bacteria, including Bifidobacterium and Lactobacillus. These good bacteria were replaced by members of the Proteobacteria family. Overall, the infants who received antibiotics shortly after birth had less diversity of their gut microbiome 4 and 8 weeks after antibiotic treatment, despite the fact that some beneficial bacteria had recovered.||The information from this study may or may not apply to infants whose mothers receive IV antibiotics during labor for GBS, because these infants received antibiotics after birth. The most common antibiotic given for GBS during labor is penicillin, with cefazolin, clindamycin, and vancomycin being given less frequently.
|Keski-Nisula et al. 2013
|Researchers collected vaginal swabs from 50 mothers approximately 21 days before birth. They also swabbed the baby’s mouth immediately after birth. They only included mother-baby pairs in the final data analysis if the mother had Lactobacillus present in the vagina prenatally, and they excluded babies born by elective Cesarean when the membranes were intact. 17 women received antibiotics during labor—indications for the antibiotics included GBS, suspected chorioamnionitis, and Cesarean.||45 of the 50 women were colonized with Lactobacilli in the last trimester, and 14 of their newborns were also colonized with Lactobacilli dominant mixed flora after birth. The researchers found that longer duration of ruptured membranes and IV antibiotics during labor were independent predictors of a decreased transmission of Lactobacillus to the baby. Of babies born to the 45 mothers who were colonized with Lactobacilli- only 1 baby exposed to antibiotics during labor was colonized with Lactobacillus at birth, while half of the newborns (16 in total) who were not exposed to IV antibiotics during labor were colonized with Lactobacillus at birth.||Researchers are not sure why longer durations of ruptured membranes led to a decreased colonization with Lactobacillus. The researchers state that research is needed to determine if giving to probiotics to mothers and newborns immediately after birth can help lessen the impact of IV antibiotics on the baby’s microbiome.|
|Aloisio et al. (2014)
|Collected stool samples from 52 newborns in an Italian NICU at 6 to 7 days after birth. Half of these newborns were born to mothers who had IV antibiotics for GBS, and the other half were born to mothers who were GBS negative and did not receive antibiotics during labor. All of the babies were born vaginally at term and were exclusively breastfed.||All types of bacteria that they tested for were present in both groups; however, the number (counts) of some types of bacteria differed between groups. In the group that was exposed to IV antibiotics during labor, there were lower counts of E. coli and Bifidobacterium, but there were no differences between groups in the average counts of Bacteroides fragilis group, lactobacilli, and C. difficile. In the newborns whose mothers received antibiotics, there was less diversity of the Bifidobacterium that were present.||The authors stated that the most important difference was a significant reduction in bifidobacteria counts (one type of beneficial bacteria) at 1 week of life in infants whose birthing parents received IV antibiotics.|
|Aloisio (2016)||Collected stool samples at 7 days of age from 10 babies born to GBS-negative mothers who did not receive antibiotics during labor and 10 babies born to GBS-positive mothers who received antibiotics during labor. The 20 newborns in this study were in the NICU at the time their samples were collected, and were all born vaginally at term and had been exclusively breastfed. The authors used a special genetic (DNA) analysis to look at the genetic diversity of the bacteria, called “next generation sequencing.”||The infants whose parents had not received antibiotics had a more “rich” and complex microbial profile, while the babies whose birthing parent had received in-labor antibiotics had very poor diversity of their microbiome, higher levels of gram-negative bacteria, and a decrease in beneficial bacteria such as Bifidobacterium, Bacteroidetes, and Actinobacteria. There were higher levels of gram-negative bacteria, Enterobacteriaceae, and Proteobacteria in the IV antibiotics group.
|The authors stated that there were clear differences in the gut microbiome between the two groups at one week of age. They also state that the changes in the microbiome are consistent with what one would expect after administering an IV antibiotic like ampicillin that mainly acts against gram-positive bacteria, leading to an over-abundance of gram-negative bacteria.|
|Researchers enrolled 198 mother-infant pairs from a large Canadian cohort study. The infants included in this sub-study had stool samples collected at 3 and 12 months, and complete data about antibiotic exposure during labor and after birth. Infants were separated into 4 groups: no antibiotic exposure during labor with vaginal delivery (57%), antibiotic exposure with vaginal birth (21%), antibiotic exposure with elective Cesarean (9%), and antibiotic exposure with unplanned Cesarean (13%). Cefazolin was used during Cesareans, and penicillin was used during vaginal births. Researchers also measured the presence and duration of exclusive breastfeeding. They used high through-put genetic sequencing to determine the infant gut microbiome.||Among vaginal births, GBS was the most common reason for antibiotic use during labor (76%), followed by prolonged rupture of membranes (24%). Half (52%) of the infants were exclusively breastfed at 3 months, and half (49%) were still receiving breast milk at one year.
The results showed that the infant microbiome was influenced by antibiotic exposure, route of delivery, and breastfeeding. At 3 months, infants exposed to antibiotics during labor had a decreased level of Bacteroidetes, as well as a decrease in microbiome richness, regardless of breastfeeding status. The most severe deficiencies happened among infants born by Cesarean. Infants born by Cesarean also had higher levels of Clostridium, Enterococcus, and Streptococcus. At one year of age, most of the differences were gone, although some differences remained in infants who were not breastfed for at least 3 months.
|This was the most thorough study so far in terms of measuring antibiotic exposure during labor and during the first year of life, as well as breastfeeding. Breastfeeding had the beneficial effect of helping the microbiome recover after antibiotic exposure—the benefits increased with exclusive breastfeeding and with an increased breastfeeding duration. Although by one year of age the gut seemed to have recovered in all infants who were breastfed for at least 3 months, the researchers were not able to rule out long-term health effects from the initial microbiome changes before that. It is not surprising that Bacteroidetes (a type of beneficial bacteria) were suppressed at 3 months following antibiotic exposure during labor, given that this type of bacteria is sensitive to penicillin and cefazolin.|
|Researchers enrolled 84 healthy term infants whose mothers had all been screened for GBS. They excluded infants born by Cesarean, who received antibiotics after birth, those admitted to the NICU, or those whose mothers had antibiotics before labor. Stool samples were collected at 7 and 30 days of life, and infants were separated into two groups: those whose mother received antibiotics during labor for GBS, or those whose mother was GBS-negative and did not receive antibiotics during labor. Researchers also collected info on breastfeeding. None of the parents gave their infants probiotics after birth. They researchers counted the number of these beneficial bacteria: Bifidobacterium, Lactobacillus, and B. fragilis (includes Bacteroides).||The number of Bificobacterium was lower in the antibiotic group at 7 days of life, but there were no differences between groups at 30 days. There were no differences in Lactobacillus or B. fragilis group bacteria at either time point. There were higher counts of Bifidobacterium at 7 days among infants who did not receive antibiotics during labor and those who were exclusively breastfed. By 30 days, there was no relationship between Bifidobacterium and feeding type or antibiotics.||The authors concluded that the counts of these bacteria were only temporarily lowered by antibiotic use during labor. However, this study is limited by its use of simple bacterial counts of only 3 bacterial groups, and no examination of microbiome richness, although they did use molecular techniques that improves the accuracy of bacterial counts.|
|Researchers enrolled 26 infants from the NICU in a hospital in Italy. Infants could be in the study if they were born vaginally at term, had a normal weight at birth (2.5 to 4 kg) and their mothers were screened for GBS at 35-37 weeks. Stool samples were collected at 7 days and 30 days of life. Infants were separated into 4 groups: breastfed infants born to GBS-negative mothers who did not receive antibiotics during labor (“breast fed control”), breastfed infants born to GBS positive mothers who received antibiotics during labor, mixed-fed infants born to GBS negative mothers (“mixed fed control”), and mixed-fed infants born to GBS positive mothers who received antibiotics during labor.||Among breastfed infants, the researchers found a lower diversity of bacteria at 7 and 30 days in infants who received antibiotics during labor compared to the control group. The most prominent differences at day 7 were found with higher numbers of Enterobacteriacaea family (Escherichia) and lower numbers of Bifidobacterium. By day 30, the bifidobacteria had recovered, but there were still higher levels of Enterobacteriaceae in the infants exposed to antibiotics during labor.
Mixed-fed infants exposed to antibiotics had higher numbers of Proteobacteria, Firmicutes, Streptococcus, and bacteria from the Enterobacteriaceae family when compared to mixed fed control infants at 7 days. The control groups who were mixed-fed had higher levels of Actinobacteria and Bacteroidetes, and Bifidobacterium at 7 days. By day 30, the two mixed-fed groups looked more similar in terms of their microbiome.
There was less diversity and richness in the microbiome of breastfed infants exposed to antibiotics during labor, compared to mixed-fed infants exposed to antibiotics during labor.
|These researchers are not sure why the breastfed infants exposed to antibiotics during labor fared worse in terms of richness and diversity of their microbiome profile, compared to mixed-fed infants exposed to antibiotics. They propose that perhaps there are effects of the antibiotics on breast milk when the mother is exposed to antibiotics during labor, but this needs further study. They also state that we need research on probiotic supplements to help newborns balance the microbiome after antibiotic exposure during labor.|